MTOR inhibitors in cancer therapy

Cancer Letters

Volumn 319, Issue 1, 2012, Pages 1-7

  Zaytseva, Yekaterina Y ^a   Valentino, Joseph D ^a,b   Gulhati, Pat ^c   Mark Evers, B ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cancer; Cancer therapy; Drug resistance; MTOR

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; AZD 2014; AZD 8055; BEVACIZUMAB; BGT 226; ERLOTINIB; EVEROLIMUS; GDC 0980; GSK 2126458; INK 128; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; OSI 027; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RIDAFOROLIMUS; S6 KINASE; SELUMETINIB; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ASTROCYTOMA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE ARREST; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; COMPETITIVE INHIBITION; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; ENDOMETRIUM CANCER; EPITHELIOID SARCOMA; FATIGUE; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; OSTEOSARCOMA; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SHORT SURVEY; SIDE EFFECT; SOFT TISSUE CANCER; SOLID TUMOR; WALDENSTROEM MACROGLOBULINEMIA;

MAMMALIA;

EID: 84858082548     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.005     Document Type: Review

References (61)

1. Zoncu R., Efeyan A., Sabatini D.M. MTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
2. Laplante M., Sabatini D.M. MTOR signaling at a glance. J. Cell Sci. 2009, 122:3589-3594.
3. Menon S., Manning B.D. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27(Suppl. 2):S43-S51.
4. Kim D.H., Sabatini D.M. Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr. Top Microbiol. Immunol. 2004, 279:259-270.
5. Manning B.D., Cantley L.C. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans. 2003, 31:573-578.
6. Gibbons J.J., Abraham R.T., Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 2009, 36(Suppl. 3):S3-S17.
7. Hara K., Yonezawa K., Kozlowski M.T., Sugimoto T., Andrabi K., Weng Q.P., Kasuga M., Nishimoto I., Avruch J. Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 1997, 272:26457-26463.
8. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA 2008, 105:17414-17419.
9. Sabatini D.M. MTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6:729-734.
10. Efeyan A., Sabatini D.M. MTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol. 2010, 22:169-176.
11. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
12. Yu Y., Yoon S.O., Poulogiannis G., Yang Q., Ma X.M., Villen J., Kubica N., Hoffman G.R., Cantley L.C., Gygi S.P., Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332:1322-1326.
13. Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322.
14. Yecies J.L., Manning B.D. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 2011, 71:2815-2820.
15. Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., Griffiths J.R., Chung Y.L., Schulze A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008, 8:224-236.
16. Laplante M., Sabatini D.M. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 2009, 19:R1046-R1052.
17. Edinger A.L., Thompson C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol Cell. 2002, 13:2276-2288.
18. Foster K.G., Fingar D.C. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem. 2010, 285:14071-14077.
19. Zinzalla V., Stracka D., Oppliger W., Hall M.N. Activation of mTORC2 by association with the ribosome. Cell 2011, 144:757-768.
20. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
21. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha but not S6K1. Dev. Cell 2006, 11:859-871.
22. Garcia-Martinez J.M., Alessi D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 2008, 416:375-385.
23. Alvarado Y., Mita M.M., Vemulapalli S., Mahalingam D., Mita A.C. Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Target Oncol. 2011, 6:69-94.
24. Wander S.A., Hennessy B.T., Slingerland J.M. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J. Clin. Invest. 2011, 121:1231-1241.
25. Hardt M., Chantaravisoot N., Tamanoi F. Activating mutations of TOR (target of rapamycin). Genes Cells 2011, 16:141-151.
26. Gulhati P., Cai Q., Li J., Liu J., Rychahou P.G., Qiu S., Lee E.Y., Silva S.R., Bowen K.A., Gao T., Evers B.M. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin. Cancer Res. 2009, 15:7207-7216.
27. Chiang G.G., Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 2007, 13:433-442.
28. Murakami M., Ichisaka T., Maeda M., Oshiro N., Hara K., Edenhofer F., Kiyama H., Yonezawa K., Yamanaka S. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell Biol. 2004, 24:6710-6718.
29. Gangloff Y.G., Mueller M., Dann S.G., Svoboda P., Sticker M., Spetz J.F., Um S.H., Brown E.J., Cereghini S., Thomas G., Kozma S.C. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell Biol. 2004, 24:9508-9516.
30. Roulin D., Cerantola Y., Dormond-Meuwly A., Demartines N., Dormond O. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol. Cancer 2010, 9:57.
31. Wu W.K., Lee C.W., Cho C.H., Chan F.K., Yu J., Sung J.J. RNA interference targeting raptor inhibits proliferation of gastric cancer cells. Exp. Cell Res. 2011, 317:1353-1358.
32. Guertin D.A., Stevens D.M., Saitoh M., Kinkel S., Crosby K., Sheen J.H., Mullholland D.J., Magnuson M.A., Wu H., Sabatini D.M. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009, 15:148-159.
33. Masri J., Bernath A., Martin J., Jo O.D., Vartanian R., Funk A., Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007, 67:11712-11720.
34. Gulhati P., Bowen K.A., Liu J., Stevens P.D., Rychahou P.G., Chen M., Lee E.Y., Weiss H.L., O'Connor K.L., Gao T., Evers B.M. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011, 71:3246-3256.
35. Zhang F., Zhang X., Li M., Chen P., Zhang B., Guo H., Cao W., Wei X., Cao X., Hao X., Zhang N. mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. Cancer Res. 2010, 70:9360-9370.
36. Liu L., Luo Y., Chen L., Shen T., Xu B., Chen W., Zhou H., Han X., Huang S. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J. Biol. Chem. 2010, 285:38362-38373.
37. Zhou H., Huang S. mTOR signaling in cancer cell motility and tumor metastasis. Crit. Rev. Eukaryot. Gene Expr. 2010, 20:1-16.
38. Patel V., Marsh C.A., Dorsam R.T., Mikelis C.M., Masedunskas A., Amornphimoltham P., Nathan C.A., Singh B., Weigert R., Molinolo A., Gutkind J.S. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res. 2011.
39. Capdevila J., Salazar R., Halperin I., Abad A., Yao J.C. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev. 2011, 30(Suppl 1):27-34.
40. Li J., Liu J., Song J., Wang X., Weiss H.L., Townsend C.M., Gao T., Evers B.M. mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. Am. J. Physiol. Cell Physiol. 2011.
41. Liu Q., Thoreen C., Wang J., Sabatini D., Gray N.S. mTOR mediated anti-cancer drug discovery. Drug Discov. Today Ther. Strateg. 2009, 6:47-55.
42. Zeng Z., Sarbassov dos D., Samudio I.J., Yee K.W., Munsell M.F., Ellen Jackson C., Giles F.J., Sabatini D.M., Andreeff M., Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007, 109:3509-3512.
43. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci. Signal 2009, 2:pe24.
44. Guertin D.A., Guntur K.V., Bell G.W., Thoreen C.C., Sabatini D.M. Functional genomics identifies TOR-regulated genes that control growth and division. Curr. Biol. 2006, 16:958-970.
45. Garcia-Echeverria C. Blocking the mTOR pathway: a drug discovery perspective. Biochem. Soc. Trans. 2011, 39:451-455.
46. Zhang H., Bajraszewski N., Wu E., Wang H., Moseman A.P., Dabora S.L., Griffin J.D., Kwiatkowski D.J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 2007, 117:730-738.
47. Hudes G.R. mTOR as a target for therapy of renal cancer. Clin. Adv. Hematol. Oncol. 2007, 5:772-774.
48. Morrisett J.D., Abdel-Fattah G., Hoogeveen R., Mitchell E., Ballantyne C.M., Pownall H.J., Opekun A.R., Jaffe J.S., Oppermann S., Kahan B.D. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J. Lipid Res. 2002, 43:1170-1180.
49. Yu K., Toral-Barza L., Shi C., Zhang W.G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., Cole D.C., Ellingboe J., Ayral-Kaloustian S., Mansour T.S., Gibbons J.J., Abraham R.T., Nowak P., Zask A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69:6232-6240.
50. Roper J., Richardson M.P., Wang W.V., Richard L.G., Chen W., Coffee E.M., Sinnamon M.J., Lee L., Chen P.C., Bronson R.T., Martin E.S., Hung K.E. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 2011, 6:e25132.
51. Shor B., Gibbons J.J., Abraham R.T., Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009, 8:3831-3837.
52. Zask A., Verheijen J.C., Curran K., Kaplan J., Richard D.J., Nowak P., Malwitz D.J., Brooijmans N., Bard J., Svenson K., Lucas J., Toral-Barza L., Zhang W.G., Hollander I., Gibbons J.J., Abraham R.T., Ayral-Kaloustian S., Mansour T.S., Yu K. ATP-competitive inhibitors of the mammalian target of rapamyc: design and synthesis of highly potent and selective pyrazolopyrimidines. J. Med. Chem. 2009, 52:5013-5016.
53. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., Garcia-Echeverria C., Weissleder R., Mahmood U., Cantley L.C., Wong K.K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
54. Janes M.R., Limon J.J., So L., Chen J., Lim R.J., Chavez M.A., Vu C., Lilly M.B., Mallya S., Ong S.T., Konopleva M., Martin M.B., Ren P., Liu Y., Rommel C., Fruman D.A. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 2010, 16:205-213.
55. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
56. Xie X., Ghadimi M.P., Young E.D., Belousov R., Zhu Q.S., Liu J., Lopez G., Colombo C., Peng T., Reynoso D., Hornick J.L., Lazar A.J., Lev D. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin. Cancer Res. 2011, 17:5901-5912.
57. Zhao H., Cui K., Nie F., Wang L., Brandl M.B., Jin G., Li F., Mao Y., Xue Z., Rodriguez A., Chang J., Wong S.T. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res. Treat. 2011.
58. Salazar R., Reidy-Lagunes D., Yao J. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs 2011, 71:841-852.
59. Roulin D., Waselle L., Dormond-Meuwly A., Dufour M., Demartines N., Dormond O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol. Cancer 2011, 10:90.
60. Gedaly R., Angulo P., Hundley J., Daily M.F., Chen C., Koch A., Evers B.M. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res. 2010, 30:4951-4958.
61. Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., Gray N.S., Sabatini D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.